However, examination of genetic alterations and transcript level of LSD1 gene from 38 cancer types containing approximate 10 000 samples from The Cancer Genome Atlas (TCGA) database revealed overall very low incidence of mutation rate, low frequency of loss or gains of LSD1, and negligible changes of its mRNA levels across most cancers (Figure S1A,B and Tables S1 and S2, Supporting Information), suggesting dysregulated LSD1 signaling occurs largely through post‐translational modifications of this demethylase.[16]. Here, MBD2 is linked to cancer.